MaxCyte Latest News

On the Charge: MaxCyte Celebrates Role in Sickle Cell Therapy Breakthrough

After interviewing Maher Masoud and Jim Brady, Kevin Davies, editor of GEN, presents in this article an exploration of MaxCyte’s history, its impact on the cell and gene therapy field—especially following the casgevy approval—and a glimpse into its future. READ ARTICLE >>

December 12, 2024

MaxCyte Minutes Newsletter – Q4 2024

In the last three months, new collaboration between the University of California San Diego Sanford Stem Cell Institute (SSCI) and MaxCyte, Webinar on Next-Generation genetic discovery systems in human immune cells, Scientific poster on High efficiency complex gene editing of hard-to-transfect primary cells using MaxCyte electroporation in combination with Synthego sgRNAs.

December 11, 2024

MaxCyte puts a focus on Jeremy Kolenbrander, SVP, Product Development and Engineering

Jeremy Kolenbrander is Senior VP of Product Development and Engineering at MaxCyte, he was drawn to cell and gene therapy as it has the ability to make a huge difference in the lives of patients and their caregivers. He joined MaxCyte in early in 2024.

November 13, 2024

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

MaxCyte marks over a quarter-century remaining steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technical and regulatory support, to develop biomedical innovations that will transform human health.

November 11, 2024

MaxCyte announces collaboration with University of California San Diego

New collaboration aims to improve patient outcomes and boost biopharma workforce development.

October 15, 2024

MaxCyte appoints Cynthia Collins to its board of directors

Cynthia Collins joins the board with extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years.

October 10, 2024

MaxCyte appoints Ali Soleymannezhad as Chief Commercial Officer

Ali Soleymannezhad will lead MaxCyte’s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the company’s market impact in cell and gene therapy.

September 25, 2024

MaxCyte Minutes Newsletter – Q3 2024

In the last three months, Kamau Therapeutics became a strategic platform licensee partner, Porton Advance adopted the ExPERT GTx Flow Electroporation as part of their offerings, and ScaleReady and MaxCyte have collaborated on the G-Rex Grant Program to support cell and gene therapy advancements.

September 24, 2024

MaxCyte puts a focus on Marina Prasek, Director of Project Management

Marina Prasek is a project and portfolio management leader with demonstrated success in new product development and commercialization that joined MaxCyte in January of 2024.

September 16, 2024

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

MaxCyte and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, announce they are entering into a strategic platform license (SPL) agreement.

August 29, 2024

MaxCyte Announces Collaboration with ScaleReady to Participate in the G-Rex Grant Program

MaxCyte’s electroporation expertise and equipment are available to all G-Rex grant recipients through an exclusive offer, including a discounted instrument, one pack of non-GMP processing assemblies and an ExPERT Platform Starter Pack.